Newsroom | 23225 results

VENLO, Niederlande, und GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Verfügbarkeit von zwei maßgeschneiderten digitalen PCR-Assays für Forschungszwecke (Research Use Only, RUO) bekannt gegeben. Diese sollen Forschungs- und Überwachungsmaßnahmen im Zusammenhang mit dem Ausbruch des Bundibugyo-Ebolavirus unterstützen. Die Assays wurden für den Einsatz mit dem digitalen PCR-System QIAcuity entwickelt und sollen qualifizierten Laboren dabei...

VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater s...

SEATTLE--(BUSINESS WIRE)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo. Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI’s proprietary SLA-SE adjuvant. The acquisition underscores the growing recogni...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live w...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress. GSK licensed bepirovirsen from Ionis an...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ : HYFT), une société de recherche et de technologie thérapeutique alimentée par l'IA bio-native, a annoncé aujourd'hui le lancement de sa plateforme de réponse aux pandémies, une configuration de déploiement de son système propriétaire de modèles biologiques HYFT® et de la plateforme LensAI™, tous deux spécialement conçus pour la préparation aux épidémies, la conception rapide de contre-mesures et la génération d'antigènes et d'ant...

LOS ANGELES--(BUSINESS WIRE)--Alors que l’Ouganda et la République démocratique du Congo (RDC) sont confrontés à une épidémie d’Ebola qui évolue rapidement, l’AIDS Healthcare Foundation (AHF) met en garde contre le fait que cette crise met en lumière les faiblesses persistantes de la capacité mondiale à répondre rapidement et équitablement aux menaces liées aux maladies infectieuses émergentes. L’épidémie actuelle implique la souche Bundibugyo du virus Ebola, pour laquelle aucun vaccin ni trait...

LOS ANGELES--(BUSINESS WIRE)--Angesichts des sich rasch ausbreitenden Ebola-Ausbruchs in Uganda und der Demokratischen Republik Kongo (DRK) warnt die AIDS Healthcare Foundation (AHF), dass diese Krise die anhaltenden Schwächen der weltweiten Fähigkeit offenbart, schnell und gerecht auf neu auftretende Bedrohungen durch Infektionskrankheiten zu reagieren. Der aktuelle Ausbruch betrifft den Ebola-Stamm „Bundibugyo“, für den es derzeit keine zugelassenen Impfstoffe oder Therapeutika gibt, was laut...

SAN DIEGO--(BUSINESS WIRE)--Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that its recently completed Phase 3 clinical trial of CANDIN® (Purified Candida albicans Antigen), the Company’s investigational immunotherapeutic therapy for the treatment and resolution of common warts (Verruca vulgaris) met its primary endpoint as well as key secondary endpoints. The topline results of the trial were presented earlier this month at t...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The Platform draws on the same biological intelligence in...